Keywords: UK, Value-based drug pricing, House of Commons health committee, NICE, Cancer Drug Fund, Clinical trials data access, ABPI

UK's value-based pricing system plans lack clarity, MPs find

Article | 17 January 2013

The UK government’s plans to overhaul the National Health Service pricing system for new drugs are poorly explained, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in